Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Radius raises $91M privately for PhIII osteoporosis trial, and then goes public

This article was originally published in Scrip

Executive Summary

Radius Health has unveiled a $91 million funding round, including $66 million in equity financing and a $25 million loan facility, which will mainly be used for a Phase III, 2,400-patient fracture trial of its novel bone-building drug BA058 – an anabolic agent - as a treatment for severe osteoporosis patients. Virtually simultaneously, the company backed into a public company shell and plans to migrate to the Nasdaq exchange by the beginning of 2010.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts